The upward trend in the immunotherapy utilization for hepatobiliary cancers

作     者：Xiao-Bu Lan George Papatheodoridis Yu-Xian Teng Jian-Hong Zhong 

作者机构：Department of PharmacyThe Fifth Affiliated Hospital of Guangxi Medical UniversityNanningChina Department of GastroenterologyMedical School of National and Kapodistrian University of AthensGeneral Hospital of Athens“Laiko”AthensGreece Department of Hepatobiliary SurgeryGuangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research CenterGuangxi Medical University Cancer HospitalNanningChina 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2021年第10卷第5期

页      面：692-695页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This work was supported by the National Natural Science Foundation of China(no.82060510) “Guangxi BaGui Scholars”Special Fund(no.2019AQ20) and the Natural Science Foundation of Guangxi Province(no.2020GXNSFAA159022). 

主　　题：immunotherapy mortality biliary 

摘      要：Hepatobiliary cancers(HBCs)include those of the liver[mainly hepatocellular carcinoma(HCC)and intrahepatic cholangiocarcinoma]and biliary tract(extrahepatic cholangiocarcinoma and gallbladder cancer).Based on the 2020 global cancer statistics,liver cancer ranks seventh in incidence and third in mortality among all malignant tumors,while gallbladder cancer ranks 25th in incidence and 21st in mortality(1).Due to the lack of typical symptoms and signs at the early stages,HBCs are often diagnosed at intermediate or advanced stages,and thus the opportunity of curative surgical interventions is missed(2).Therefore,most patients with HBC can only be treated with noncurative treatments,including immunotherapy.Several immunotherapeutic approaches have been attempted for HBCs,including oncolytic viruses,tumor vaccines,adoptive immunotherapy,and immune checkpoint inhibitors(ICIs;Figure 1).